Arcus Biosciences (RCUS) Stock Statistics & Valuation Metrics

Arcus Biosciences has a market cap or net worth of $2.77B. The enterprise value is $2.10B.

Arcus Biosciences has 125,349,480 shares outstanding. The number of shares has decreased by -2.65% in one year.

Arcus Biosciences’s return on equity (ROE) is -0.56 and return on invested capital (ROIC) is -42.51%.

The current PE Ratio of Arcus Biosciences is ―. Arcus Biosciences’s PEG ratio is -1.52.

In the last 12 months, Arcus Biosciences had revenue of 247.00M and earned -353.00M in profits. Earnings per share was -3.29.

In the last 12 months, operating cash flow was -482.00M and capital expenditures -2.00M, giving a free cash flow of -484.00M billion.

Arcus Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―

Arcus Biosciences upcoming earnings date is May 12, 2026, After Close (Confirmed).

Arcus Biosciences as a current ratio of 4.36, with Debt / Equity ratio of 15.69%

In the past 12 months, Arcus Biosciences has paid 0.00 in taxes.

Arcus Biosciences EV to EBITDA ratio is -7.27, with an EV/FCF ratio of -5.03.

Arcus Biosciences has $981.00M in cash and marketable securities with $99.00M in debt, giving a net cash position of $882.00M billion.

Gross margin is 97.98%, with operating margin of -156.28%, and net profit margin of -142.91%.

The average price target for Arcus Biosciences is $32.11, which is 11.43% higher than the current price. The consensus rating is Moderate Buy